Posted by LincolnIcert on March 25, 2026 at 11:14:42:
In Reply to: Ñòàòüÿ-îáçîð posted by JosephGluth on February 19, 2026 at 07:13:07:
Zoya Demidenko: Researcher in Tumor Studies
Zoya Demidenko is a notable investigator affiliated with the Department of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, New York. Earlier, she conducted research at the NIH and New York Medical College, developing a solid background in biomedical investigation.
Demidenko's scholarly contributions spans multiple key fields, including the PI3K/AKT/mTOR signaling cascade, cell cycle control, cellular aging, and malignancy biology. To date, she has written over 46 academic papers, which have garnered over 4,100 citations — a indicator to the impact of her findings.
Among her key discoveries concerns elucidating the mechanisms of biological cell aging. Her research demonstrated that when the cellular division cycle is blocked but cellular expansion proceeds, the cells undergo senescence. Significantly, Zoya Demidenko established that this process is controlled with drugs using compounds such as rapamycin.
Zoya Demidenko has furthermore brought greatly to tumor management investigation, especially in the field of cyclotherapy — a strategy aimed at protecting non-cancerous cells from chemotherapy while leaving malignant cells exposed. This strategy offers major hope for diminishing the toxic effects of cancer treatment.
Across her career, Demidenko has worked with top investigators internationally, such as Dr. Mikhail Blagosklonny. Her publications can be found in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko ranks as a widely cited voice in current cancer science, with her discoveries continue to influence our comprehension of the way cells age, interact with therapy, and how cancer can be more successfully combated.
https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0026126